EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation

Reza Elahi, Yassine Alami Idrissi, Anwaar Saeed

Cancer Treatment Reviews · 2025-12 · 141 · 103046

DOI: 10.1016/j.ctrv.2025.103046 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2025-12. Verfasst von Reza Elahi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology & Oncology, Department of Medicine, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15232, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 236 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)-T cell therapy has transformed cancer immunotherapy, achieving durable complete remissions in hematologic cancers. Yet its translation to solid tumors like hepatocellular carcinoma (HCC), a leading cause of cancer-related deaths worldwide, faces formidable barriers, including immunosuppressive tumor microenvironments (TMEs), antigen heterogeneity, and risks of on-target/off-tumor toxicity. This review discusses the evolving role of CAR-T therapy in HCC across three domains: (1) foundational concepts in CAR-T design, mechanistic action, and antigen-targeting strategies; (2) breakthroughs from preclinical studies and early-phase clinical trials, such as glypican-3 (GPC3) and alpha-fetoprotein (AFP) directed CAR-T cells that have demonstrated preliminary safety and anti-tumor activity; and (3) innovative strategies to overcome TME-driven resistance, including metabolic reprogramming and stromal modulation. We highlight cutting-edge engineering solutions such as armored CAR-T cells engineered for cytokine support, dual-targeting constructs to mitigate antigen escape, and hypoxia-resistant designs alongside synergistic approaches combining CAR-T with immune checkpoint inhibitors or tyrosine kinase inhibitors. Furthermore, we dissect emerging tactics to disrupt TME immunosuppression. While CAR-T therapy holds promise for redefining HCC management, its success will depend on overcoming biological and logistical barriers through patient-tailored designs and robust translational pipelines. Future directions should prioritize biomarker-driven clinical trials, scalable manufacturing platforms, and integration with existing multimodal HCC therapies to maximize durable responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansTumor Microenvironment

Stichwörter der Autor:innen

Immunotherapychimeric antigen receptor (CAR)hepatocellular carcinoma (HCC)tumor microenvironment (TME)

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Division of Hematology & Oncology, Department of Medicine, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15232, USA.
  • Department of internal medicine, Maimonides medical center, Brooklyn, NY 11219, USA.
  • Division of Hematology & Oncology, Department of Medicine, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15232, USA. Electronic address: saeeda3@upmc.edu.

Zitieren

APA

Elahi, R., Alami Idrissi, Y., & Saeed, A. (2025). CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation. Cancer Treatment Reviews, 141, 103046. https://doi.org/10.1016/j.ctrv.2025.103046

Vancouver

Elahi R, Alami Idrissi Y, Saeed A. CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation. Cancer Treatment Reviews. 2025;141:103046. doi:10.1016/j.ctrv.2025.103046

BibTeX
@article{Elahi2025,
  author = {Elahi, Reza and Alami Idrissi, Yassine and Saeed, Anwaar},
  title = {CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation},
  journal = {Cancer Treatment Reviews},
  year = {2025},
  volume = {141},
  pages = {103046},
  doi = {10.1016/j.ctrv.2025.103046}
}
Kostenlos starten →